Physician

Wenqing Zhang, PHD, MD

According to 2025 Medicare claims, Wenqing Zhang, PHD, MD (NPI: 1720286594) practices medical oncology in the Homosassa Springs, FL market, with the plurality of this provider's patient population coming from Citrus, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34453-3879. Zhang is affiliated with the St. Luke's Medicare ACO (ACO ID: A3560), participating under the MSSP model.

Zhang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 981 traditional Medicare patients, billed 436,312 HCPCS/CPT codes, and received $4,256,815 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,468 prescription claims across 327 beneficiaries totaling $4,959,580 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 48 claims. Open Payments data shows 200 records totaling $10,892. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $100,832 to $4,256,815. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,195,973 and ending at $4,959,580. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	295	1,295	$100,832
2016	501	2,581	$104,199
2017	423	2,661	$96,028
2018	468	3,460	$138,635
2019	424	6,614	$162,937
2020	960	171,302	$3,072,587
2021	525	25,272	$487,979
2022	411	14,752	$161,324
2023	920	163,129	$1,393,802
2024	981	436,312	$4,256,815

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	183	1,061	$1,195,973
2016	189	666	$396,710
2017	174	891	$786,518
2018	208	1,202	$1,284,390
2019	180	564	$617,014
2020	213	1,303	$743,338
2021	221	758	$457,765
2022	124	459	$1,047,707
2023	170	501	$1,460,662
2024	327	1,468	$4,959,580

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	60	$5,323
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$5,942
2022	N/R	12	$6,755
2023	N/R	N/R	N/R
2024	N/R	48	$34,251

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	244	306	$132
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	559	1,519	$94
96372	Injection of drug or substance under skin or into muscle	315	1,339	$11
36415	Insertion of needle into vein for collection of blood sample	736	3,098	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	689	2,987	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	53	1,590	$905,321
Revlimid	Lenalidomide	39	1,092	$687,704
Brukinsa	Zanubrutinib	47	1,410	$519,991
Calquence	Acalabrutinib Maleate	32	960	$456,672
Pomalyst	Pomalidomide	12	336	$269,760

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	11	$33,599
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$407
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$188
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	11	$57

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	197	$5,262	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$5,630	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Wenqing Zhang, PHD, MD?

Tedicare shows public-source Medicare data for Wenqing Zhang, PHD, MD (NPI 1720286594), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Wenqing Zhang, PHD, MD have ACO affiliation data?

Wenqing Zhang, PHD, MD is shown with ACO affiliation data for St. Luke's Medicare ACO (MSSP, ACO ID A3560).

What billing organization is linked to Wenqing Zhang, PHD, MD?

Wenqing Zhang, PHD, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Wenqing Zhang, PHD, MD have Open Payments data?

Wenqing Zhang, PHD, MD has 200 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.